GCIBelluscura poised for growth: record sales of X-PLOR and launch of DISCOV-R signal turnaround
Commercialising breakthrough technology (eg Nvidia, Tesla, Apple, etc) is never easy, even at the best of times.
The important bit is not to get dispirited by setbacks, but instead adapt to challenges, learn from past mistakes, and crucially, remain positive. It's only possible to the change the future - and so during tough periods, the Board need to provide optimism, leadership, passion, and clarity of vision in order to continue engaging with the hearts and minds of all key stakeholders.
Take () , a next generation developer of portable oxygen concentrators (POCs), which has experienced its fair share of problems over the past 2 years.
This morning, the company released its Dec FY'23 results (adjusted EBITDA of -$6.3m on sales of $825k vs $1.4m), which as previously indicated had been impacted by funding issues and delays in completing the all-share £5.8m acquisition of TMT. However, that's in the rearview mirror, and a successful turnaround now appears to be taking shape.
CEO Bob Rauker, commenting: "The Group made substantial product, operations and regulatory approval development progress in 2023. Plus with record sales of the X-PLOR POC in May'24, the Company is starting to gain good traction in the US. In addition, with the initial Direct to Consumer launch of DISCOV-R in June, Belluscura is well positioned to deliver substantial growth and we look forward to the future with confidence."
Indeed, the new DISCOV-R device should be "transformational", underpinned by "very strong" demand and pre-orders worth 6,500 units. On top, a major competitor has left the market, whilst the two other rivals have larger, more bulky products compared to 's smaller and lighter POCs. Moreover, most of the development and capital costs for the DISCOV-R have already been incurred.
Finally, in July 2024 expects to raise up to $3m via a combination of equity and convertible loan notes (CLNs, subject to shareholder approval). In fact, last Monday the Board said it had already "received significant interest" for its proposed £2.4m placing of 5-year 7% CLNs.
Things definitely seem to be moving in the right direction.
Follow News & Updates from Belluscura:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.